Biblio
Export 1756 results:
Author Title [ Type] Year Filters: First Letter Of Last Name is L [Clear All Filters]
“Utility of Amyloid PET Scans in the Evaluation of Patients Presenting with Diverse Cognitive Complaints.”, J Alzheimers Dis, vol. 66, no. 4, pp. 1599-1608, 2018.
, “Utility of Amyloid and FDG-PET in Clinical Practice: Differences Between Secondary and Tertiary Care Memory Units.”, J Alzheimers Dis, vol. 63, no. 3, pp. 1025-1033, 2018.
, “Usefulness of an Integrated Analysis of Different Memory Tasks to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease: The Episodic Memory Score (EMS).”, J Alzheimers Dis, vol. 50, no. 1, pp. 61-70, 2016.
, “Use of Analgesics (Opioids and Nonsteroidal Anti-Inflammatory Drugs) and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort.”, J Alzheimers Dis, vol. 58, no. 2, pp. 435-448, 2017.
, “Urine-Based Biomarkers for Alzheimer's Disease Identified Through Coupling Computational and Experimental Methods.”, J Alzheimers Dis, vol. 65, no. 2, pp. 421-431, 2018.
, “Urine Formaldehyde Predicts Cognitive Impairment in Post-Stroke Dementia and Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1031-1038, 2017.
, “Urine Formaldehyde Predicts Cognitive Impairment in Post-Stroke Dementia and Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1031-1038, 2017.
, “Urine Formaldehyde Predicts Cognitive Impairment in Post-Stroke Dementia and Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1031-1038, 2017.
, “Urine Formaldehyde Predicts Cognitive Impairment in Post-Stroke Dementia and Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1031-1038, 2017.
, “Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer's Disease and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 60, no. 1, pp. 87-95, 2017.
, “Urban Air Pollution Nanoparticles from Los Angeles: Recently Decreased Neurotoxicity.”, J Alzheimers Dis, vol. 82, no. 1, pp. 307-316, 2021.
, “Urban Air Pollution Nanoparticles from Los Angeles: Recently Decreased Neurotoxicity.”, J Alzheimers Dis, vol. 82, no. 1, pp. 307-316, 2021.
, “Upregulation of Connexin 43 Expression Via C-Jun N-Terminal Kinase Signaling in Prion Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1005-19, 2016.
, “Upregulated Expression of Heparanase and Heparanase 2 in the Brains of Alzheimer's Disease.”, J Alzheimers Dis, vol. 58, no. 1, pp. 185-192, 2017.
, “An Update on Type 2 Diabetes Mellitus as a Risk Factor for Dementia.”, J Alzheimers Dis, vol. 53, no. 2, pp. 393-402, 2016.
, “Untold New Beginnings: Adult Hippocampal Neurogenesis and Alzheimer's Disease.”, J Alzheimers Dis, vol. 64, no. s1, pp. S497-S505, 2018.
, “Unstable Body Mass Index and Progression to Probable Alzheimer's Disease Dementia in Patients with Amnestic Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 49, no. 2, pp. 483-91, 2016.
, “Unstable Body Mass Index and Progression to Probable Alzheimer's Disease Dementia in Patients with Amnestic Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 49, no. 2, pp. 483-91, 2016.
, “Unlocking Modifiable Risk Factors for Alzheimer's Disease: Does the Oral Microbiome Hold Some of the Keys?”, J Alzheimers Dis, vol. 92, no. 4, pp. 1111-1129, 2023.
, “Ultra-High Field MRI in Alzheimer's Disease: Effective Transverse Relaxation Rate and Quantitative Susceptibility Mapping of Human Brain In Vivo and Ex Vivo Compared to Histology.”, J Alzheimers Dis, vol. 73, no. 4, pp. 1481-1499, 2020.
, “Ultra-High Field MRI in Alzheimer's Disease: Effective Transverse Relaxation Rate and Quantitative Susceptibility Mapping of Human Brain In Vivo and Ex Vivo Compared to Histology.”, J Alzheimers Dis, vol. 73, no. 4, pp. 1481-1499, 2020.
, “UCH-L1 Inhibition Decreases the Microtubule-Binding Function of Tau Protein.”, J Alzheimers Dis, vol. 49, no. 2, pp. 353-63, 2016.
, “Type 1 Diabetes Mellitus and Cognitive Impairments: A Systematic Review.”, J Alzheimers Dis, vol. 57, no. 1, pp. 29-36, 2017.
, “Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome.”, J Alzheimers Dis, vol. 95, no. 3, pp. 887-899, 2023.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
,